Chronic graft versus host disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:25:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chronic graft versus host disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments https://clinicaltrials.eu/trial/study-of-axatilimab-compared-to-standard-therapy-in-children-with-chronic-graft-versus-host-disease-who-have-previously-received-at-least-2-treatments/ Thu, 30 Apr 2026 13:08:12 +0000 https://clinicaltrials.eu/trial/study-of-axatilimab-compared-to-standard-therapy-in-children-with-chronic-graft-versus-host-disease-who-have-previously-received-at-least-2-treatments/ This study focuses on Chronic Graft-Versus-Host Disease, a condition that can occur after a stem cell transplant when the donated cells attack the recipient’s body. The study will evaluate a new medication called axatilimab, given as an intravenous solution, compared to currently available treatments in children and teenagers who have already tried at least two other treatments that didn’t work well enough.

The purpose of this research is to determine how well axatilimab works compared to other standard treatments in managing chronic graft-versus-host disease. During the study, participants will receive either axatilimab or one of several commonly used treatments for this condition. The treatment period may continue for up to 24 months.

Throughout the study, doctors will monitor how participants respond to treatment, including changes in their symptoms and overall health. They will also track how well participants can reduce their use of corticosteroids, which are commonly used to treat this condition. The study will collect information about quality of life and check for any side effects of the treatment.

]]> Study of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment https://clinicaltrials.eu/trial/study-of-belumosudil-in-children-aged-1-to-18-years-with-moderate-to-severe-chronic-graft-versus-host-disease-requiring-systemic-treatment/ Thu, 30 Apr 2026 13:08:06 +0000 https://clinicaltrials.eu/trial/study-of-belumosudil-in-children-aged-1-to-18-years-with-moderate-to-severe-chronic-graft-versus-host-disease-requiring-systemic-treatment/ This study focuses on children with chronic graft versus host disease (cGVHD), a condition that can occur after receiving cells from a donor during a stem cell transplant. The disease happens when the donated cells attack the recipient’s body, causing inflammation and damage to various organs. The study will test a medication called belumosudil, which is available as both film-coated tablets and oral suspension that can be taken by mouth or through a feeding tube.

The study aims to find the right dose of belumosudil for children and determine how well it works in treating moderate to severe chronic graft versus host disease. The research is divided into two parts. In the first phase, researchers will work to establish the appropriate dose for children. In the second phase, they will evaluate how many children respond positively to the treatment.

During the study, participants will receive belumosudil and will be monitored regularly to check their response to the treatment. The medication can be taken either as tablets or as a liquid suspension, depending on what works best for each child. The study will track how well the medication helps to control the symptoms of chronic graft versus host disease and will also monitor the safety of the treatment in children.

]]> A Study of Belumosudil for Patients with Steroid-Resistant Overlap Syndrome Graft-versus-Host Disease https://clinicaltrials.eu/trial/a-study-of-belumosudil-for-patients-with-steroid-resistant-overlap-syndrome-graft-versus-host-disease/ Wed, 29 Apr 2026 15:08:01 +0000 https://clinicaltrials.eu/trial/a-study-of-belumosudil-for-patients-with-steroid-resistant-overlap-syndrome-graft-versus-host-disease/ This study involves patients with a condition called steroid-refractory overlap syndrome Graft-versus-Host-Disease, which can occur after a stem cell transplant when the donated immune cells attack the recipient’s body. This condition is called an overlap syndrome because it has features of both the early and late forms of this disease. When the disease does not respond well to treatment with steroids, it is considered steroid-refractory. The treatment being studied is a medication called belumosudil, which is given as a film-coated tablet taken by mouth. Patients will receive up to 400 milligrams of the medication daily for a treatment period that can last up to 52 weeks.

The purpose of this study is to evaluate how well belumosudil works in patients with moderate to severe steroid-refractory overlap syndrome Graft-versus-Host-Disease by measuring the overall response rate at week 25 of treatment. During the study, patients will take belumosudil tablets daily while doctors monitor their condition through regular visits. The study will track whether the disease improves, stays the same, or gets worse, and whether patients need additional treatments. Doctors will also look at how symptoms change over time, particularly by measuring improvements in symptom scores and whether patients can reduce or stop taking steroids.

Throughout the study, doctors will monitor various aspects of patient health and disease response. This includes checking how different organs affected by the disease respond to treatment, measuring changes in immune cells in the blood, and assessing overall survival and quality of life. The study will also track any side effects or unwanted reactions that patients may experience while taking belumosudil. Blood tests and physical examinations will be performed regularly to evaluate how the treatment is working and to ensure patient safety during the entire treatment period.

]]> Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments https://clinicaltrials.eu/trial/study-comparing-axatilimab-to-best-available-therapy-for-patients-with-chronic-graft-versus-host-disease-after-two-or-more-treatments/ Wed, 29 Apr 2026 15:05:09 +0000 https://clinicaltrials.eu/trial/study-comparing-axatilimab-to-best-available-therapy-for-patients-with-chronic-graft-versus-host-disease-after-two-or-more-treatments/ This clinical trial is focused on studying Chronic Graft-Versus-Host Disease (cGVHD), a condition that can occur after a stem cell or bone marrow transplant. In this disease, the donated cells attack the recipient’s body, leading to various symptoms. The study will compare the effectiveness of a new treatment called Axatilimab (INCA034176), which is given as a solution for infusion, against the best available therapy currently used for cGVHD.

The purpose of the study is to see how well Axatilimab works compared to other treatments. Participants in the study will receive either Axatilimab or one of the existing treatments, which may include medications like cyclosporine, tacrolimus, or other therapies. The study will monitor participants over a period to assess their response to the treatment and any changes in their condition.

Throughout the study, participants will be observed for improvements in their symptoms and any side effects they may experience. The goal is to determine if Axatilimab can provide a better outcome for those with cGVHD who have already tried at least two other treatments. This research aims to offer new hope for managing this challenging condition.

]]> Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients https://clinicaltrials.eu/trial/study-on-axatilimab-and-corticosteroids-for-initial-treatment-of-chronic-graft-versus-host-disease-in-patients/ Wed, 29 Apr 2026 15:03:03 +0000 https://clinicaltrials.eu/trial/study-on-axatilimab-and-corticosteroids-for-initial-treatment-of-chronic-graft-versus-host-disease-in-patients/ This clinical trial is focused on studying a condition known as chronic graft-versus-host disease (cGVHD). This is a complication that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The study will explore the effectiveness of a new treatment involving a medication called Axatilimab (INCA034176), used in combination with corticosteroids, which are a type of steroid medication. The trial will also include a comparison with a placebo to evaluate the treatment’s effectiveness.

The purpose of the study is to compare how well Axatilimab works in combination with corticosteroids compared to a placebo in treating moderate or severe cases of cGVHD. Participants in the study will receive either the new treatment or a placebo, and their progress will be monitored over time. The study will involve regular check-ups and assessments to track the condition and any changes in symptoms.

Participants will be randomly assigned to different groups to ensure a fair comparison between the new treatment and the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to prevent bias in the results. The trial will continue for a set period, during which the safety and effectiveness of the treatment will be closely monitored.

]]> Study of Axatilimab for Patients with Chronic Graft Versus Host Disease After Two Prior Treatments https://clinicaltrials.eu/trial/study-of-axatilimab-for-patients-with-chronic-graft-versus-host-disease-after-two-prior-treatments/ Wed, 29 Apr 2026 15:01:49 +0000 https://clinicaltrials.eu/trial/study-of-axatilimab-for-patients-with-chronic-graft-versus-host-disease-after-two-prior-treatments/ This clinical trial is focused on studying a condition known as Chronic Graft Versus Host Disease (cGVHD). This is a complication that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The treatment being tested in this study is a medication called Axatilimab, which is given as a solution through an intravenous infusion. The study aims to evaluate the effectiveness, safety, and tolerability of Axatilimab at three different doses in patients who have cGVHD that has not responded to at least two previous treatments.

Participants in the study will receive Axatilimab at one of three doses: 0.3 mg/kg every two weeks, 1 mg/kg every two weeks, or 3 mg/kg every four weeks. The study will observe how well the treatment works and monitor any side effects. The goal is to see if Axatilimab can help reduce the symptoms of cGVHD and improve the quality of life for those affected by this condition.

The study will take place over a period of time, with regular check-ups and assessments to track the participants’ progress. This includes monitoring vital signs, conducting physical examinations, and evaluating the response to the treatment. The information gathered from this study will help determine the potential benefits of Axatilimab for patients with cGVHD who have limited treatment options.

]]> Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease https://clinicaltrials.eu/trial/study-on-axatilimab-and-ruxolitinib-for-patients-with-newly-diagnosed-chronic-graft-versus-host-disease/ Wed, 29 Apr 2026 14:59:44 +0000 https://clinicaltrials.eu/trial/study-on-axatilimab-and-ruxolitinib-for-patients-with-newly-diagnosed-chronic-graft-versus-host-disease/ This clinical trial is focused on studying a condition known as chronic graft-versus-host disease (cGVHD). This condition can occur after a bone marrow or stem cell transplant, where the donated cells attack the recipient’s body. The study will explore the effects of a treatment combining two medications: Axatilimab and Ruxolitinib. Axatilimab, also known by its code name INCA034176, is given as a solution for infusion, which means it is administered directly into the bloodstream. Ruxolitinib, also known as Jakavi, is taken in tablet form and works by selectively inhibiting certain enzymes involved in the immune response.

The purpose of this study is to evaluate the safety and effectiveness of the combination of Axatilimab and Ruxolitinib in people who have been newly diagnosed with cGVHD. Participants in the study will receive these medications over a period of up to 24 months. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatment. The study will monitor how well the treatment works and any side effects that may occur.

Throughout the study, participants will have regular check-ups to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information on whether the combination of Axatilimab and Ruxolitinib can improve outcomes for individuals with cGVHD. This research could potentially lead to better treatment options for those affected by this challenging condition.

]]> Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ruxolitinib-panobinostat-and-siremadlin-for-patients-continuing-treatment-from-previous-studies/ Wed, 29 Apr 2026 14:59:37 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ruxolitinib-panobinostat-and-siremadlin-for-patients-continuing-treatment-from-previous-studies/ This clinical trial is focused on evaluating the long-term safety of treatments for patients who have previously participated in studies involving the medication ruxolitinib, either alone or in combination with other drugs. Ruxolitinib is a medication used to treat certain types of blood disorders. In this study, it may be combined with other medications such as panobinostat, siremadlin (also known as HDM201), or rineterkib. The purpose of the study is to gather information on the safety of these treatments over a longer period.

Participants in this study will continue their treatment with ruxolitinib or its combinations as they have been doing in their previous studies. The study will monitor the frequency and severity of any side effects or adverse events that occur during the treatment. This information will help researchers understand the long-term safety of these medications and their combinations.

The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. It is conducted at multiple centers, allowing for a diverse group of participants. The study aims to provide valuable data on the safety of these treatments, which can benefit future patients who may receive these medications. Participants will be assessed regularly to determine any clinical benefits they may experience from the continued treatment.

]]> Study on Ruxolitinib and Methoxsalen for Patients with Steroid-Refractory Chronic Graft-versus-Host Disease https://clinicaltrials.eu/trial/study-on-ruxolitinib-and-methoxsalen-for-patients-with-steroid-refractory-chronic-graft-versus-host-disease/ Wed, 29 Apr 2026 14:58:37 +0000 https://clinicaltrials.eu/trial/study-on-ruxolitinib-and-methoxsalen-for-patients-with-steroid-refractory-chronic-graft-versus-host-disease/ This clinical trial is focused on studying a condition known as steroid-refractory chronic Graft-versus-Host Disease (SR-cGvHD). This is a condition that can occur after a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The study will explore the effects of two treatments used together: ruxolitinib, a medication taken as a tablet, and a procedure called extracorporeal photopheresis (ECP). ECP is a process where blood is treated outside the body to help manage the disease.

The purpose of the study is to evaluate the safety and effectiveness of combining these treatments for patients with SR-cGvHD. Participants will receive both ruxolitinib and ECP over a period of time, and their response to the treatment will be monitored. The study will assess how well the combination works in reducing the symptoms of SR-cGvHD and improving the overall health of the participants.

Throughout the study, participants will have regular visits to track their progress and any changes in their condition. The study aims to provide valuable information on whether this combined treatment approach can offer a new option for managing SR-cGvHD, especially for those who have not responded well to standard steroid treatments.

]]> Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease https://clinicaltrials.eu/trial/study-of-belumosudil-and-prednisone-for-patients-aged-12-and-older-with-newly-diagnosed-chronic-graft-versus-host-disease/ Wed, 29 Apr 2026 14:57:05 +0000 https://clinicaltrials.eu/trial/study-of-belumosudil-and-prednisone-for-patients-aged-12-and-older-with-newly-diagnosed-chronic-graft-versus-host-disease/ This clinical trial is focused on studying a condition called chronic graft versus host disease (cGVHD). This condition can occur after a person receives a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The study is testing a new oral medication called belumosudil, which is being used in combination with corticosteroids, a type of medication that helps reduce inflammation and suppress the immune system. The trial will compare the effects of belumosudil combined with corticosteroids against a placebo combined with corticosteroids.

The purpose of the study is to see if belumosudil, when used with corticosteroids, is more effective than corticosteroids alone in improving the condition of patients with newly diagnosed cGVHD. Participants in the study will be randomly assigned to receive either the combination of belumosudil and corticosteroids or a placebo and corticosteroids. The study will monitor participants over a period to assess their health and any changes in their condition.

Throughout the study, participants will take the medication orally, and their progress will be closely observed by the research team. The trial aims to provide valuable information on the safety and effectiveness of belumosudil in treating cGVHD, potentially offering a new treatment option for those affected by this condition.

]]> Study on the Safety and Effectiveness of Ibrutinib for Children and Young Adults with Chronic Graft Versus Host Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ibrutinib-for-children-and-young-adults-with-chronic-graft-versus-host-disease/ Wed, 29 Apr 2026 14:30:24 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-ibrutinib-for-children-and-young-adults-with-chronic-graft-versus-host-disease/ This clinical trial is focused on studying a condition known as Chronic Graft Versus Host Disease (cGVHD), which can occur after a stem cell transplant. The study is investigating the use of a medication called Ibrutinib, which is being tested in different forms such as a suspension for oral use, film-coated tablets, and hard capsules. The purpose of the study is to find the right dose and to assess the safety and effects of Ibrutinib in children and young adults with cGVHD.

The study is divided into two parts. In the first part, researchers aim to determine the appropriate dose of Ibrutinib for children aged 1 to under 12 years. In the second part, the focus is on understanding how the body processes the medication and its safety in participants aged 1 to under 22 years. Participants in the study may have moderate or severe cGVHD that has not responded to previous treatments. Some participants may also be newly diagnosed with cGVHD and require systemic immunosuppression, which is a treatment to reduce the activity of the immune system.

Throughout the study, participants will receive either Ibrutinib or a placebo. The study will monitor the response to the treatment over a period of time, including the duration of response and overall survival rate. Additionally, the study will observe the growth and development of pediatric participants. The trial is expected to continue until November 2025, with the aim of providing valuable information on the use of Ibrutinib in treating cGVHD in younger patients.

]]> Continued Treatment Study for Patients with Myelofibrosis, Post-Lung Transplant BOS, or Chronic Graft-Versus-Host Disease Using Itacitinib https://clinicaltrials.eu/trial/continued-treatment-study-for-patients-with-myelofibrosis-post-lung-transplant-bos-or-chronic-graft-versus-host-disease-using-itacitinib/ Wed, 29 Apr 2026 14:24:22 +0000 https://clinicaltrials.eu/trial/continued-treatment-study-for-patients-with-myelofibrosis-post-lung-transplant-bos-or-chronic-graft-versus-host-disease-using-itacitinib/ This clinical trial is focused on providing continued treatment for participants who have been previously enrolled in studies involving the medication Itacitinib (also known by its code name INCB039110). The diseases being studied in this trial include Myelofibrosis, a condition where scar tissue forms in the bone marrow, chronic graft-versus-host disease, which can occur after a stem cell or bone marrow transplant, and bronchiolitis obliterans syndrome (BOS) that can develop after a lung transplant.

The purpose of this study is to continue evaluating the safety of Itacitinib for participants who are experiencing clinical benefits from this treatment. Participants will continue to receive the medication in tablet form, taken orally, as part of their ongoing care. The study is designed to monitor any side effects or adverse events that may occur while participants are on this medication.

Throughout the study, participants will have scheduled visits to ensure their treatment is progressing safely and effectively. The study aims to provide a seamless transition for those who have been benefiting from Itacitinib in previous trials, allowing them to continue their treatment under careful observation. The study is expected to run until 2027, ensuring long-term support and monitoring for participants.

]]>